Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
5-day change
1st Jan Change
36.42
USD
+1.62%
+4.54%
+18.32%
Collegium Pharmaceutical, Inc.'s Equity Buyback announced on January 4, 2023, has expired with 3,088,069 shares, representing 9.09% for $75 million.
The company expired its plan on December 31, 2023.
Collegium Pharmaceutical to Redeem $26.35 Million of Senior Notes
Apr. 11
MT
Piper Sandler Adjusts Price Target on Collegium Pharmaceutical to $39 From $37, Maintains Overweight Rating
Feb. 26
MT
Truist Adjusts Price Target on Collegium Pharmaceutical to $40 From $37, Maintains Buy Rating
Feb. 26
MT
Collegium Pharmaceutical's Q4 Adjusted Earnings, Revenue Increase
Feb. 23
MT
Transcript : Collegium Pharmaceutical, Inc., Q4 2023 Earnings Call, Feb 22, 2024
Feb. 22
Earnings Flash (COLL) COLLEGIUM PHARMACEUTICAL Reports Q4 EPS $1.58, vs. Street Est of $1.26
Feb. 22
MT
Collegium Pharmaceutical, Inc. Reaffirms Earnings Guidance for the Full Year 2024
Feb. 22
CI
Collegium Pharmaceutical, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Feb. 22
CI
Collegium Pharmaceutical, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Feb. 22
CI
North American Morning Briefing : Bond Yields Rise -2-
Jan. 05
DJ
Truist Adjusts Collegium Pharmaceutical's Price Target to $37 From $31, Keeps Buy Rating
Jan. 04
MT
Jefferies Downgrades Collegium Pharmaceutical to Hold From Buy, Raises Price Target to $37 From $30
Jan. 04
MT
North American Morning Briefing: S&P 500 Futures Nudge Higher After Weak Start to the Year
Jan. 04
DJ
Health Care Dips on Defensive Rotation - Health Care Roundup
Jan. 03
DJ
Collegium Pharmaceutical Expects Net Product Revenue of up to $595 Million in 2024
Jan. 03
MT
Tranche Update on Collegium Pharmaceutical, Inc.'s Equity Buyback Plan announced on January 4, 2023.
Jan. 03
CI
Collegium Pharmaceutical, Inc. announces an Equity Buyback for $150 million worth of its shares.
Jan. 03
CI
Collegium Pharmaceutical, Inc. Provides Earnings Guidance for the Year 2024
Jan. 03
CI
Collegium Pharmaceutical, Inc. authorizes a Buyback Plan.
Dec. 31
CI
Collegium Pharmaceutical, Inc.'s Equity Buyback announced on January 4, 2023, has expired with 3,088,069 shares, representing 9.09% for $75 million.
Dec. 30
CI
Collegium Pharmaceutical Insider Sold Shares Worth $2,075,086, According to a Recent SEC Filing
Dec. 21
MT
Transcript : Collegium Pharmaceutical, Inc., Q3 2023 Earnings Call, Nov 07, 2023
Nov. 07
Earnings Flash (COLL) COLLEGIUM PHARMACEUTICAL Posts Q3 EPS $1.34, vs. Street Est of $1.24
Nov. 07
MT
Earnings Flash (COLL) COLLEGIUM PHARMACEUTICAL Reports Q3 Revenue $136.7M, vs. Street Est of $139.5M
Nov. 07
MT
Collegium Pharmaceutical, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Nov. 07
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Collegium Pharmaceutical, Inc. is a diversified specialty pharmaceutical company. The Company commercializes its pain portfolio, consisting of Xtampza extended-release (ER), Nucynta ER and Nucynta immediate-release (IR), Belbuca, and Symproic in the United States. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone. Xtampza ER is a pain treatment option designed with abuse deterrent properties and uses a technology platform, DETERx. The Nucynta Products are ER and IR oral formulations of tapentadol. Nucynta ER is indicated for the management of severe and persistent pain that requires an extended treatment period with a daily opioid analgesic. Nucynta IR is indicated for the management of acute pain severe enough to require an opioid analgesic. Belbuca is a buccal film that contains buprenorphine for severe and persistent pain. Symproic is used for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain.
More about the company
Last Close Price
36.42
USD
Average target price
40
USD
Spread / Average Target
+9.83%
Consensus
1st Jan change
Capi.
+18.32% 1.19B +25.83% 661B +27.00% 566B -6.76% 352B +20.34% 332B +3.00% 283B +13.09% 231B +5.46% 200B -9.61% 195B -6.26% 145B
Other Pharmaceuticals
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1